Want to see OCGN full AI Analyst Report?
OCGN Stock Chart & Stats
$1.21
$0.05(4.13%)
At close: 4:00 PM EDT
$1.21
$0.05(4.13%)
Day’s Range― - ―
52-Week Range$0.93 - $2.73
Previous Close$1.26
Volume5.01M
Average Volume (3M)8.17M
Market Cap
$402.84M
Enterprise Value$594.30
Total Cash (Recent Filing)$31.86M
Total Debt (Recent Filing)$33.30M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Aug 06, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding338,521,850
10 Day Avg. Volume4,592,933
30 Day Avg. Volume8,170,514
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)-33.31
Price to Sales (P/S)91.83
P/FCF Ratio-7.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.67Price Target Upside698.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$4.37M
Bulls Say, Bears Say
Bulls Say
Regulatory RMAT For OCU410RMAT status supports an expedited and enriched FDA engagement model, potentially shortening development timelines and facilitating accelerated pathways. This materially de-risks OCU410’s regulatory path and can improve the program’s strategic value and partnerability over the next several quarters.
OCU400 MENA Licensing Term SheetThe MENA license diversifies commercialization routes, supplies near-term non-dilutive fees and structured milestone economics, and commits Ocugen to manufacture supply. This strengthens long-term revenue optionality and regional market access if OCU400 achieves approval.
Extended Cash Runway From Convertible NotesThe convertible financing repaid higher-cost debt and extends funding into 2028, allowing Ocugen to advance pivotal trials, regulatory filings, and manufacturing plans without immediate refinancing. That funding stability supports execution of late-stage programs over the medium term.
Bears Say
Persistent Operating LossesSustained negative operating cash flow and deep losses mean the business cannot self-fund development. Ongoing cash burn forces reliance on external capital or partnerships, increasing dilution risk and the chance that funding gaps could delay programs or strategic initiatives.
Stressed Balance Sheet And Rising DebtA weakened capital structure with rising debt and negative equity reduces financial flexibility and raises refinancing and covenant risks. High leverage can constrain R&D and commercial investments or force costly financings, hindering execution around critical regulatory milestones.
Very Small Revenue Base And Margin ShortfallLimited product revenue relative to operating cost creates a persistent margin gap. Even with improving trends, the company needs successful product launches or material partnership deals to reach sustainable profitability; absent that, margin recovery is uncertain.
Ocugen News
OCGN FAQ
What was Ocugen Inc’s price range in the past 12 months?
Ocugen Inc lowest stock price was $0.93 and its highest was $2.73 in the past 12 months.
What is Ocugen Inc’s market cap?
Ocugen Inc’s market cap is $402.84M.
When is Ocugen Inc’s upcoming earnings report date?
Ocugen Inc’s upcoming earnings report date is Aug 06, 2026 which is in 5 days.
How were Ocugen Inc’s earnings last quarter?
Ocugen Inc released its earnings results on May 05, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.051 by -$0.009.
Is Ocugen Inc overvalued?
According to Wall Street analysts Ocugen Inc’s price is currently Undervalued.
Does Ocugen Inc pay dividends?
Ocugen Inc does not currently pay dividends.
What is Ocugen Inc’s EPS estimate?
Ocugen Inc’s EPS estimate is -0.05.
How many shares outstanding does Ocugen Inc have?
Ocugen Inc has 338,521,850 shares outstanding.
What happened to Ocugen Inc’s price movement after its last earnings report?
Ocugen Inc reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.051. Following the earnings report the stock price went down -19.459%.
Which hedge fund is a major shareholder of Ocugen Inc?
Currently, no hedge funds are holding shares in OCGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocugen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.67 (698.90% Upside)
$9.67 (698.90% Upside)
Blogger Sentiment
Bullish
OCGN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.72%
Trailing 12-Months
Company Description
Ocugen Inc
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
OCGN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial scientific and operational progress across multiple gene‑therapy programs (OCU400, OCU410, OCU410ST) including completed Phase 3 enrollment, strong early efficacy signals (46% lesion reduction, 50% responder rate, ~two-line LLVA gain, 60% slower EZ loss), a peer‑reviewed publication, a regional licensing deal, recent capital raise, and senior hires to support commercialization. Counterbalancing these positives are a limited cash runway into 2026 (dependence on uncertain warrant exercise and future financings), rising R&D spend (~24% year) and small/preliminary datasets that require confirmatory Phase 3 results. Overall, the highlights (clinical progress, regulatory alignment, partnerships, fundraising, leadership additions) meaningfully outweigh the risks, though execution and financing remain key near‑term priorities.View all OCGN earnings summariesOCGN Stock 12 Month Forecast
Average Price Target
$9.67
▲(698.90% Upside)
Technical Analysis
Ownership Overview
2.65% Insiders
5.46% Mutual Funds
1.05% Other Institutional Investors
76.08% Public Companies and
Individual Investors